

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kiu Hung International Holdings Limited

僑雄國際控股有限公司

(Incorporated in the Cayman Islands with limited liability and continued in Bermuda with limited liability)

(Stock Code: 00381)

SUPPLEMENTAL ANNOUNCEMENT IN RESPECT OF ACQUISITION FRAMEWORK AGREEMENT

References is made to the announcement (the “**Announcement**”) of Kiu Hung International Holdings Limited (the “**Company**”) dated 4 November 2020, in relation to the entering into of the Acquisition Framework Agreement in relation to the Possible Acquisition. Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise specified.

SUPPLEMENTAL INFORMATION OF THE VENDOR AND THE TARGET COMPANY

Ms. Zhang Li (as the Vendor) is the holder of a bachelor’s degree in economics from School of Economics of Peking University, and is specialized in molecular virology at National Institute for Viral Disease Control and Prevention, China CDC. Currently, she is the legal person of Target Company.

The Target Company is a company incorporated in the People’s Republic of China with limited liability on 16 October 2017, and is principally engaged in technology development and technical services in the field of biomedical technology, as well as investments in and establishment of pharmaceutical projects and other industries.

The Target Company aims to operate and create a biotechnology collaborative innovation base with influence at home and abroad, which integrates the transformation of achievements, project incubation, scientific research, and talent exchange through a biotechnology collaborative innovation center. For the purpose of providing one-stop technological services to the government and enterprises, the Target Company pursues the mission to carry out applied science research and product development in the fields of genetic engineering, cell engineering, protein engineering and diagnostics, polymer materials, and public hygiene, to incubate and cultivate outstanding technology projects, and accelerate the development of the industry by fully tapping to its advantages over scientific and technological resources and the technological innovation advantages of the Guangdong-

Hong Kong-Macao Greater Bay Area, as well as attracting outstanding talents at home and abroad. The Target Company's product line will be primarily comprised of those under National Class I New Drugs in China.

Set forth below is a summary of the team members of the Target Company:

Full Name	Position/ Academic Status	Achievements and Honors	Responsibility
Pan Wei (潘衛)	Professor	Besides being a professor and a doctoral supervisor, he is the director at the Department of Pathogenic Biology of The Second Military Medical University. (The Second Military Medical University). He is also a deputy chairman of the Interferon Professional Committee of the Chinese Society of Microbiology. Furthermore, he is a member and secretary general of the Standing Medical Virus Professional Committee of the Chinese Medical Association.	Biostructure research
Yuelong Shu (舒躍龍)	Researcher	He is a researcher, and serves as currently the deputy director of the National Institute for Viral Disease Control and Prevention, China CDC. Besides being the director of the Chinese National Influenza Center, he concurrently serves as a member of the Asia-Pacific Advisory Committee on Influenza and an expert in the influenza prevention and control expert panel under the Ministry of Health. Furthermore, he is the director of School of Basic Medical Sciences, Sun Yat-sen University.	Technical Instructions
Zheng Lishu (鄭麗舒)	Doctor	She is a doctor and researcher, and serves as the master's degree supervisor at the National Institute for Viral Disease Control and Prevention, China CDC. Currently, she is the technology expert at Shenzhen Liyunde Bio-technology Company Limited.	Pharmacodynamics Research

Full Name	Position/ Academic Status	Achievements and Honors	Responsibility
Tong Xudong (唐旭東)	Doctor	He is a postdoctoral researcher in Basic Medical Sciences at National Institute for Viral Disease Control and Prevention, China CDC, as well as a local leading high-level professional talent in Shenzhen. In addition, he currently serves as the director and researcher of the Key Lab for New Drugs Research of TCM in Shenzhen (Tsinghua University). Furthermore, he is a technical consultant of Shenzhen Liyunde Bio-technology Company Limited.	Technical Instructions
Yuan Yi (袁嫫)	Doctor	She is a doctor in biology at School of Life Sciences, Tsinghua University, and serves as an assistant researcher in nano-oncology at the National Center for Nanoscience and Technology, Chinese Academy of Sciences. Furthermore, she is a postdoctoral researcher at National Institute for Viral Disease Control and Prevention, China CDC.	Pharmacology and toxicology
Zhang Li (張莉)	Bachelor	She is a holder of a bachelor's degree in economics from School of Economics, Peking University, and is specialized in molecular virology at National Institute for Viral Disease Control and Prevention, China CDC. Currently, she is the legal person of Shenzhen Liyunde Bio-technology Company Limited.	Legal representative and chairman of the board
Xu Dahai (許大海)	Master	He is a holder of a bachelor's degree in foreign languages at Fuyang Normal University, as well as a MBA degree at University of Turin. In addition, he is a holder of an EMBA degree in senior human resources management from Shanghai Advanced Institute of Finance, at Shanghai Jiaotong University. Previously, he served as a lecturer at the Department of Foreign Languages, Chaohu University. Since 1999, he has been working at a company engaged in genetic technology and pharmaceuticals, and currently serves as the deputy general manager, who is responsible for capital operation and market expansion.	General manager

Full Name	Position/ Academic Status	Achievements and Honors	Responsibility
Song Yuli (宋瑜麗)	Master	She holds a bachelor's degree in biology and a master's degree in business administration, and is a biopharmaceutical engineer. She previously worked in a listed biotechnology company for approximately 20 years, responsible for quality management and R & D management of biological products. She is experienced in biopharmaceutical system management. She is currently in charge of quality-related issues of Shenzhen Liyunde Bio-technology Company Limited.	Deputy general manager
Xu Chen (徐晨)	Doctor	He obtained his master's degree from Peking Union Medical College and postdoctoral degree from Harvard Medical School. He had been engaged in research and medical promotion campaigns for a gene pharmaceutical joint-stock limited company for more than 10 years.	Medical head
Yang Dajun (楊大軍)	Master	He holds a bachelor's degree from West China Faculty of Medical Sciences, Sichuan University and a master's degree from Peking Union Medical College. He studied in Japan for two years and tutored by Mr. Satoshi Omura, the winner of Nobel Prize for Medicine in 2015. He has been in charge of production quality in a biopharmaceutical company since 1998.	General responsible for production
Niu Chun (牛春)	Master	He holds a master's degree in medical information from Nanjing University and is a senior science and technology fund manager and pharmaceutical registrar. He was a lecturer in the Department of Cell Biology at Capital Medical University. He was a post-doctoral researcher in the Department of Medicine at the University of Texas in the United States as an exchange visiting scholar in 2000. Since 2001, he has been serving as a registered manager in a genetic pharmaceutical company.	Registration system

Full Name	Position/ Academic Status	Achievements and Honors	Responsibility
Zhou Minyi (周敏毅)	Master	He graduated from Beijing University of Chemical Technology with a master's degree, and had been engaged in technology research for 8 years in a genetic drug company in Beijing. He is a patent technology lawyer and has applied for more than 40 domestic and foreign invention patents, with over 100 patent applications in total.	Technical patent

Set forth below are the existing patents of the Target Company:

Patent 1: a novel interferon α and its preparation method, composition and use

Patentee: the Target Company

Patent number: ZL-2018-1-1437104.3

Application date: 28 November 2018

Patent 2: a novel interferon $\alpha 1$ and its preparation method, composition and use

Patentee: the Target Company

Patent number: ZL-2018-1-1437107.7

Application date: 28 November 2018

As indicated by the preliminary valuation report obtained by the Company from the independent professional valuer, the valuation of the Target Company is not less than HK\$100 million.

The above information is supplemental to information as contained in the Announcement.

By Order of the Board
Kiu Hung International Holdings Limited
Zhang Qijun
Chairman

Hong Kong, 11 November 2020

As at the date of this announcement, the Board comprises three executive Directors, Mr. Zhang Qijun, Mr. Chen Jian and Mr. Liu Mingqing and six independent non-executive Directors, Mr. Hou Yunde, Mr. Wang Xiao Ning, Mr. Cheng Ho On, Mr. Kong Chun Wing, Mr. Lai Chi Yin, Samuel and Ms. Chen Yuxin.